 The FDA has granted Rare Pediatric Disease RPD designation for Longeveron Incs NASDAQ: LGVN Lomecel-B for Hypoplastic Left Heart Syndrome HLHS. HLHS is a rare and life-threatening congenital heart defect in infants. 